The Ohio State University (OSU), Cardinal Health and Ohio Third Frontier are investing more than $10 million in molecular imaging research by combining Ohio State’s Wright Center of Innovation in Biomedical Imaging research capabilities and Cardinal Health’s manufacturing and commercialization expertise for molecular imaging agents.
The partnership will expand the molecular imaging research program at OSU’s Wright Center of Innovation in Biomedical Imaging to include a new Molecular Imaging Technology Center. The center will house OSU’s researchers, as well as Cardinal’s radiopharmaceutical manufacturing facility and nuclear pharmacy operations. In addition, a distinguished faculty position in radiopharmaceutical chemistry--along with other researchers--will be added to OSU’s department of radiology.
“While we expect to immediately create up to a dozen highly-skilled jobs with this exciting new partnership, the true value is collaborating with Ohio State and Cardinal Health to attract the best and brightest researchers to Ohio and continue to diversify our state’s economy,” said Ohio Lieutenant Governor Lee Fisher. “The new center is expected to bring additional investment from the pharmaceutical industry, which can leverage the research and commercialization expertise offered by this partnership for new radiopharmaceutical development projects.”
As new agents move through the development pipeline, Cardinal said it will also support manufacturing and dispensing for clinical trials across its national network of radiopharmaceutical facilities.